Cargando…
P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY)
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431188/ http://dx.doi.org/10.1097/01.HS9.0000848676.15840.df |
_version_ | 1784779983799975936 |
---|---|
author | Nastoupil, L. J. O’Brien, S. Holmes, H. E. Dsouza, L. Hart, D. Matsuda, E. Satterfield-Ledbetter, T. Skoble, J. Garner, E. Bryan, M. Kanner, S. Li, E. Thomas, C. T. Essell, J. |
author_facet | Nastoupil, L. J. O’Brien, S. Holmes, H. E. Dsouza, L. Hart, D. Matsuda, E. Satterfield-Ledbetter, T. Skoble, J. Garner, E. Bryan, M. Kanner, S. Li, E. Thomas, C. T. Essell, J. |
author_sort | Nastoupil, L. J. |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-9431188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-94311882022-08-31 P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY) Nastoupil, L. J. O’Brien, S. Holmes, H. E. Dsouza, L. Hart, D. Matsuda, E. Satterfield-Ledbetter, T. Skoble, J. Garner, E. Bryan, M. Kanner, S. Li, E. Thomas, C. T. Essell, J. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431188/ http://dx.doi.org/10.1097/01.HS9.0000848676.15840.df Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
spellingShingle | Posters Nastoupil, L. J. O’Brien, S. Holmes, H. E. Dsouza, L. Hart, D. Matsuda, E. Satterfield-Ledbetter, T. Skoble, J. Garner, E. Bryan, M. Kanner, S. Li, E. Thomas, C. T. Essell, J. P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY) |
title | P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY) |
title_full | P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY) |
title_fullStr | P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY) |
title_full_unstemmed | P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY) |
title_short | P1455: FIRST-IN-HUMAN TRIAL OF CB-010, A CRISPR-EDITED ALLOGENEIC ANTI-CD19 CAR -T CELL THERAPY WITH A PD-1 KNOCK OUT, IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA (ANTLER STUDY) |
title_sort | p1455: first-in-human trial of cb-010, a crispr-edited allogeneic anti-cd19 car -t cell therapy with a pd-1 knock out, in patients with relapsed or refractory b cell non-hodgkin lymphoma (antler study) |
topic | Posters |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431188/ http://dx.doi.org/10.1097/01.HS9.0000848676.15840.df |
work_keys_str_mv | AT nastoupillj p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT obriens p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT holmeshe p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT dsouzal p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT hartd p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT matsudae p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT satterfieldledbettert p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT skoblej p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT garnere p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT bryanm p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT kanners p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT lie p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT thomasct p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy AT essellj p1455firstinhumantrialofcb010acrispreditedallogeneicanticd19cartcelltherapywithapd1knockoutinpatientswithrelapsedorrefractorybcellnonhodgkinlymphomaantlerstudy |